December 1, 2008 – Merck KGaA announced today that it has received approval from the European Commission to extend the use of its targeted therapy Erbitux (cetuximab) to include first-line treatment of patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck. Erbitux was previously approved for use in combination with radiotherapy for locally advanced disease.
The details can be read here.
No comments:
Post a Comment